Axicabtagene ciloleucel (axi-cel) and tisagenlecleucel (tisa-cel) are CD19-targeted chimeric antigen receptor (CAR) T-cells approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL). We performed a retrospective study to evaluate safety and efficacy of axi-cel and tisa-cel outside the setting of a clinical trial. Data from consecutive patients with R/R LBCL who underwent apheresis for axi-cel or tisa-cel were retrospectively collected from 12 Spanish centers. A total of 307 patients underwent apheresis for axi-cel (n=152) and tisa-cel (n=155) from Nov-2018 to Aug-2021, of which 261 (85%) received a CAR-T infusion (88% and 82%, respectively). Median time from apheresis to infusion was 41 days for axi-cel and 52 days for tisa-cel (p=0.006). None of the baseline characteristics were significantly different between both cohorts. Both cytokine release syndrome and neurologic events (NE) were more frequent in the axi-cel group (88% vs 73%, p=0.003, and 42% vs 16%, p.

中文翻译：

---

Axicabtagene ciloleucel 与 tisagenlecleucel 相比用于治疗侵袭性 B 细胞淋巴瘤。

Axicabtagene ciloleucel (axi-cel) 和 tisagenlecleucel (tisa-cel) 是 CD19 靶向嵌合抗原受体 (CAR) T 细胞，获批用于复发/难治性 (R/R) 大 B 细胞淋巴瘤 (LBCL)。我们进行了一项回顾性研究，以评估 axi-cel 和 tisa-cel 在临床试验之外的安全性和有效性。从 12 个西班牙中心回顾性收集了连续接受 axi-cel 或 tisa-cel 单采术的 R/R LBCL 患者的数据。从 2018 年 11 月到 2021 年 8 月，共有 307 名患者接受了 axi-cel (n=152) 和 tisa-cel (n=155) 单采术，其中 261 名 (85%) 接受了 CAR-T 输注 (88%)和 82%）。对于 axi-cel，从单采血液成分术到输注的中位时间为 41 天，对于 tisa-cel 为 52 天 (p=0.006)。两个队列之间的基线特征均无显着差异。